1.70
+0.1(+6.25%)
Currency In USD
| Previous Close | 1.6 |
| Open | 1.63 |
| Day High | 1.7 |
| Day Low | 1.59 |
| 52-Week High | 9.26 |
| 52-Week Low | 1.17 |
| Volume | 480,410 |
| Average Volume | 708,875 |
| Market Cap | 37.18M |
| PE | -0.18 |
| EPS | -9.29 |
| Moving Average 50 Days | 1.92 |
| Moving Average 200 Days | 2.29 |
| Change | 0.1 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $9.63 as of January 05, 2026 at a share price of $1.7. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $2.23 as of January 05, 2026 at a share price of $1.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
GlobeNewswire Inc.
Dec 03, 2025 12:00 PM GMT
Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home NEW HAVEN, Conn., Dec.
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
Completes clinical trials required by FDA for sNDA submission planned for the first quarter of 2026NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intel
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
GlobeNewswire Inc.
Oct 13, 2025 11:00 AM GMT
NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO V